NCT01362803 2026-04-14
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
Clinical Trials
62 trialsNCT02390752 2026-04-14
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT06507748 2026-04-09
A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)
National Institutes of Health Clinical Center (CC)
Phase NA Recruiting
NCT03962543 2026-04-08
ReNeu
SpringWorks Therapeutics, Inc.
Phase 2 Active not recruiting
NCT02544022 2026-04-07
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
National Institutes of Health Clinical Center (CC)
Recruiting
NCT07407803 2026-04-06
Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Recruiting
NCT03975829 2026-04-02
Pediatric Long-Term Follow-up and Rollover Study
Novartis
Phase 4 Active not recruiting
NCT06360406 2026-03-31
Real-World Treatment Study of Koselugo (Selumetinib)
AstraZeneca
Recruiting
NCT05028166 2026-03-27
Individual Patient Compassionate Use of Mirdametinib
SpringWorks Therapeutics, Inc.
Available
NCT04924608 2026-03-23
KOMET
AstraZeneca
Phase 3 Active not recruiting
NCT00924196 2026-03-20
Natural History Study of Patients With Neurofibromatosis Type I
National Institutes of Health Clinical Center (CC)
Active not recruiting
NCT06541847 2026-03-20
INSPIRE-NF1
Healx Limited
Phase 2 Recruiting
NCT06188741 2026-03-12
NF114
University of Alabama at Birmingham
Phase 2 Recruiting
NCT06502171 2026-03-12
NF113
University of Alabama at Birmingham
Phase 1 Not yet recruiting
NCT02407405 2026-03-05
MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT06104488 2026-02-25
A Study of Avutometinib for People With Solid Tumor Cancers
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT06175637 2026-02-12
PEDIA
AstraZeneca
Active not recruiting
NCT04590235 2026-01-30
A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
AstraZeneca
Phase 1 Active not recruiting
NCT06515860 2026-01-09
NF1-TED
Boston Children's Hospital
Recruiting
NCT06961565 2025-12-04
PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
Pasithea Therapeutics Corp.
Phase 1 Recruiting
NCT06222203 2025-09-26
Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)
National Institutes of Health Clinical Center (CC)
Recruiting
NCT05238909 2025-09-02
Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1
Ann & Robert H Lurie Children's Hospital of Chicago
Enrolling by invitation
NCT02777775 2025-07-24
Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.
Corewell Health West
Completed
NCT07024394 2025-06-17
Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1/2 Not yet recruiting
NCT03231306 2025-05-02
NF108-BINI
University of Alabama at Birmingham
Phase 2 Completed
NCT05683678 2025-04-04
US Selumetinib Registry
Alexion Pharmaceuticals, Inc.
Terminated
NCT05913037 2025-03-06
FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 3 Active not recruiting
NCT06763315 2025-01-08
LS-NF1PNs
West China Hospital
Phase 2 Not yet recruiting
NCT04954001 2024-11-12
Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1/2 Active not recruiting
NCT03531814 2024-06-11
Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials
National Institutes of Health Clinical Center (CC)
Phase NA Completed
NCT06379230 2024-04-23
A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE)
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Recruiting
NCT03741101 2024-04-11
plexifpc
Region Skane
Phase 2 Active not recruiting
NCT03326388 2024-04-04
INSPECT
Great Ormond Street Hospital for Children NHS Foundation Trust
Phase 1/2 Completed
NCT05199376 2024-02-09
CryoNF1
Centre Leon Berard
Phase NA Recruiting
NCT03363217 2023-11-27
Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.
St. Justine's Hospital
Phase 2 Active not recruiting
NCT05825365 2023-08-14
PROTECT
AstraZeneca
Phase 2 Withdrawn
NCT05331105 2023-05-31
HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
Shanghai Kechow Pharma, Inc.
Phase 2 Recruiting
NCT02101736 2023-05-24
NF105-CABO
University of Alabama at Birmingham
Phase 2 Completed
NCT02471339 2022-06-14
Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT02124772 2021-07-14
Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations
Novartis
Phase 1/2 Completed
NCT01800032 2021-05-12
PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)
UNC Lineberger Comprehensive Cancer Center
Completed
NCT03820778 2021-03-02
Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1
Children's National Research Institute
Phase NA Active not recruiting
NCT03688568 2021-02-12
Study of Imatinib in Children With Neurofibromatosis and Airway Tumors
Indiana University
Phase 2 Withdrawn
NCT03027401 2020-10-08
Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics
National Institutes of Health Clinical Center (CC)
Withdrawn
NCT00006435 2020-05-04
Study of Plexiform Neurofibromas in Neurofibromatosis Type 1
National Institutes of Health Clinical Center (CC)
Completed
NCT03259633 2020-05-01
An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1
AstraZeneca
Approved for marketing
NCT00340522 2019-12-16
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
National Institutes of Health Clinical Center (CC)
Completed
NCT00727233 2019-12-12
Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02177825 2019-04-08
Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas
St. Justine's Hospital
Phase 2 Terminated
NCT03109301 2019-04-05
Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn